摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-Allylamino-1,2,3,4-tetrahydro-acridin | 57165-72-7

中文名称
——
中文别名
——
英文名称
9-Allylamino-1,2,3,4-tetrahydro-acridin
英文别名
allyl-(1,2,3,4-tetrahydro-acridin-9-yl)-amine;N-prop-2-enyl-1,2,3,4-tetrahydroacridin-9-amine
9-Allylamino-1,2,3,4-tetrahydro-acridin化学式
CAS
57165-72-7
化学式
C16H18N2
mdl
——
分子量
238.332
InChiKey
BJRCBRPSACYLQE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    24.9
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • [EN] TACRINE DERIVATIVES AS INHIBITORS OF ACETYLCHOLINESTERASE<br/>[FR] DERIVES DE TACRINE UTILISES EN TANT QU'INHIBITEURS DE L'ACETYLCHOLINESTERASE
    申请人:NEUROPHARMA SA
    公开号:WO2005005413A1
    公开(公告)日:2005-01-20
    The invention provides compounds of formula: (I) which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the beta-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.
    该发明提供了具有以下公式的化合物:(I),其中通过连接剂将一种他环境基团连接到一种杂环基团。通过精心选择取代基和连接剂,可以调节对乙酰胆碱酯酶的活性和选择性。这些化合物显示出强大的AChE抑制活性,同时通过同时结合催化和外周AChE位点,改变了β-淀粉样蛋白聚集特性。它们在治疗AChE介导的疾病,如阿尔茨海默病中非常有用。
  • Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease
    申请人:Gil Martinez Ana
    公开号:US20060142323A1
    公开(公告)日:2006-06-29
    A family of compounds of formula (I) wherein: X is one of the following radicals: which behaves as dual site acetyl-cholinesterase inhibitors and which are especially useful for the treatment of cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerst-mann-Straussler-Scheiner disease.
    一种化合物家族的公式(I),其中:X是以下基团之一:这些基团表现为双位点乙酰胆碱酯酶抑制剂,特别适用于治疗认知障碍,如老年性痴呆症、脑血管性痴呆症、轻度认知障碍、注意力缺陷障碍和/或神经退行性痴呆性疾病,其中异常蛋白质聚集尤为突出,如阿尔茨海默病、帕森病、肌萎缩侧索硬化症或朊病,如克雅氏病或格斯特曼-斯特劳斯勒-谢因纳病。
  • Acetylcholinesterase dual inhibitors
    申请人:Gil Martinez Ana
    公开号:US20050148621A1
    公开(公告)日:2005-07-07
    The invention provides compounds of formula: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the β-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.
    该发明提供了公式的化合物:其中通过连接剂连接了一种Tacrine基团和一个杂环基团。通过精心选择取代基和连接剂,可以调节对乙酰胆碱酯酶的活性和选择性。这些化合物显示出强大的AChE抑制活性,同时通过同时结合催化和周围AChE位点,修改β淀粉样聚集物的聚集特性。它们在治疗AChE介导的疾病,如阿尔茨海默病中很有用。
  • ACETYLCHOLINESTERASE DUAL INHIBITORS
    申请人:Gil Ana Martinez
    公开号:US20110144148A1
    公开(公告)日:2011-06-16
    The invention provides compounds of formula: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the β-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.
    本发明提供了公式如下的化合物: 通过连接剂将Tacrine基团连接到杂环基团上。通过对取代基和连接剂的精心选择,可以调节其对乙酰胆碱酯酶的活性和选择性。这些化合物表现出强效的AChE抑制活性,并通过同时结合催化和周边AChE位点来改变β-淀粉样聚集物的聚集特性。它们在治疗AChE介导的疾病,如阿尔茨海默病方面非常有用。
  • DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    申请人:Neuropharma, S.A.
    公开号:EP1558255A2
    公开(公告)日:2005-08-03
查看更多